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DEVELOPING A MORE CLINICALLY-RELEVANT MOUSE MODEL OF 
CISPLATIN NEPHROTOXICITY 
 
Cierra N. Sharp 
 
April 25, 2016 
 
Cisplatin is a nephrotoxic chemotherapeutic that causes acute kidney 
injury (AKI) in 30% of patients.  Although recovery can occur after one episode of 
cisplatin-induced AKI, studies have indicated multiple episodes may lead to the 
development of chronic kidney disease (CKD), an irreversible disease with no 
current treatments. The standard mouse model of cisplatin-induced AKI consists 
of one, high dose of cisplatin (> 20 mg/kg) that is lethal to the animal three days 
later.  This model doesn’t accurately reflect the repeated dosing regimen patients 
receive, and doesn’t allow for long-term outcome studies of pathologies 
associated with CKD.  We have developed a repeated dosing model of cisplatin 
(7mg/kg once a week for four weeks). This model allows for the long-term 
survival of mice, and the associated pathology is fibrosis-the hallmark of CKD.  
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Acute kidney injury (AKI) is defined as a rapid loss in renal function 
accompanied by accumulation of waste products, such as urea and creatinine, in 
the blood.  According to RIFLE criteria, which aims to standardize the definition 
of AKI, AKI is associated with a 50% loss in glomerular filtration rate (GFR), a 
doubling in serum creatinine (SCr) levels, and a significant decrease in total urine 
output (1, 2).  Presently, the mortality rate of patients with AKI is 50%, and having 
AKI increases a hospital patient’s risk of death 10-15fold (3, 4).   
Cisplatin is a potent chemotherapeutic for the treatment of many solid 
tumor cancers, including ovarian, testicular, head and neck, and lung cancers (5, 
6).  While the potency of cisplatin makes it an excellent chemotherapeutic choice, 
there are very serious side effects associated with this drug.  These include bone 
marrow suppression, ototoxicity, neurotoxicity, and nephrotoxicity (7).  Of these, 
the risk of developing cisplatin-induced nephrotoxicity leading to AKI is high.  
After a single dose of cisplatin, 33% of patients will develop nephrotoxicity.  
Furthermore, cisplatin-induced AKI accounts for 19% of all cases of AKI, making 
it a prominent health problem (8).  
The high relevance of cisplatin-induced nephrotoxicity can be explained by 
the ready uptake of cisplatin in the blood and kidney.  The kidney contains 
glomeruli cells which can freely filter blood, and, as a result, cisplatin is also
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 freely filtered.  Once cisplatin is filtered through glomeruli, it is taken up by Ctr1 
and OCT2 transporters in an energy-dependent driven manner (9-11) .  These 
transporters are responsible for secretion and absorption of organic molecules.   
Once cisplatin is transported into proximal tubule cells, it is readily 
converted to a highly reactive metabolite and is conjugated to glutathione, 
proteins, RNA, and DNA (5, 12, 13).  Cisplatin causes cross-linking of DNA 
strands, thereby inhibiting DNA replication and gene transcription (6, 12, 13).  In 
the context of cancer, this is therapeutic as it leads to inhibition of growth, 
senescence, and cell death (6).  However, in the proximal tubule cells, cisplatin 
accumulates to amounts 5 times higher than that in the serum, and thus these 
processes are extremely detrimental as they lead to severe proximal tubule cell 
death, ultimately resulting in kidney injury and subsequent loss of function (6, 
14). 
Cisplatin leads to two forms of cell death in proximal tubule cells- 
apoptosis and necrosis (7). It has been well documented that cisplatin activates 
the intrinsic apoptotic cell death pathway(15).  This involves the accumulation of 
Bax, a BCL2 pro-apoptotic family member protein, in the mitochondria (16).  This 
accumulation leads to the release of cytochrome c from the mitochondria and 
eventual activation of initiator and effector caspases.  This apoptotic pathway 
plays a pivotal role in cisplatin-induced AKI pathophysiology, as Bax-/- mice are 
resistant to cisplatin nephrotoxicity (17).  
 Other BCL2 pro-apoptotic family members (such as PUMA-α) can be 
activated by p53,a tumor suppressor that is activated by DNA damage or 
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genotoxic stress (7, 18).  Activation of p53 can result in the increased 
transcription of these pro-apoptotic proteins.  Furthermore, p53 can act directly 
on BCL-2 proapoptotic family members to lead to the release of cytochrome c 
(18).  Through these mechanisms, p53 plays a pivotal role in apoptosis, both in 
terms of killing cancer, and also as a mechanism of cisplatin-induced 
nephrotoxicity.      
While apoptosis is predominately found in animal models of AKI, the main 
pathology associated with this human AKI is acute tubular necrosis (19, 20).  
Acute tubular necrosis is sudden death of the tubular epithelial cells that 
compromise the renal tubules, including both proximal and distal tubule cells(19).  
This pathology is seen in both animal and humans who have experienced AKI, 
and is often classified as acute tubular necrosis based on death to the distal 
tubules (which are affected to a greater extent than proximal tubules) and loss of 
brush borders (20).  This pathology occurs to a greater extent in animal models 
of AKI than in humans. This is due to the fact that the level of injury patients 
endure is less than the level of injury achieved in animal models used to study 
AKI.  Studies performed to examine AKI using nephrotoxins lead to very high 
levels of acute tubular necrosis due to that fact that the dose of the toxin being 
used is extremely high (20).  It has also been suggested that this discrepancy in 
human and animal pathology may be due to the fact that human kidney biopsies 
are rarely performed, and when they are, they usually do not sample the outer 
medulla where the tubules are located (21).  Furthermore, if biopsies are done, it 
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is usually during the recovery phase after AKI, and thus levels of necrosis do not 
accurately reflect levels that would be seen during injury phase (21).   
The pathophysiology of cisplatin-induced AKI not only involves tubule cell 
death, but also several other processes.  Of importance are the involvement of 
the cell cycle and immune cell infiltration/inflammatory pathways (7, 15).  The cell 
cycle is a complex system of checks and balances to ensure that cell proliferation 
occurs without fault.  Proliferation is a vital process in the kidney after injury, as 
remaining epithelial cells will dedifferentiate and proliferate to replace damaged 
tubular epithelial cells- an important step in adaptive recovery after AKI (21).     
The ability of the cell cycle to proceed from G1 to S, S to M, and M to G2 
phase in a subsequent order necessary for proper cell proliferation is controlled 
by cyclins (22).  Cyclins are periodically synthesized and degraded during the cell 
cycle, and this leads to unidirectional progression of the cell cycle.  Cyclins have 
been found to form heterodimers with Cdk subunits.  Cdk subunits are 
serine/threonine protein kinases that are only active when bound to cyclins.  
Once cyclins binds, cdk subunits take on basal kinase activity.  This kinase 
activity drives the progression of the cell cycle from one phase to another (22).   
While cyclins and their heterodimerization with Cdks are the main drivers 
of cell cycle progression, there are also protein effectors that serve as 
checkpoints to ensure that each part of the cell cycle is completed successfully, 
further ensuring that the cell cycle proceeds without fault (22).  These effectors 
monitor DNA damage, incomplete DNA synthesis, and whether or not mitosis is 
completed successfully.  These effectors primarily control the entry of cells into 
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both S and M phases by inhibiting or stimulating kinase activity of Cdks (22).  In 
humans, there are two families of protein effectors- the  CDK interacting protein/ 
kinase inhibitory protein (CIP/KIP) family and the inhibitor of cyclin-dependent 
kinase 4 (INK4) family (23).  Within the CIP/KIP family, p21 has been indicated 
as a potential therapeutic target for cisplatin-induced AKI. 
p21 is expressed constitutively at low levels in the cell.  Overexpression of 
p21, which can be induced by p53-dependent or independent mechanisms, leads 
to cyclin kinase inhibition and induction of senescence (24, 25).  p21 has been 
found to play a major role in cisplatin-induced AKI, as it determines whether or 
not tubular cells undergo cell death or survive (24).  Upon injury by cisplatin, 
many quiescent cells enter into the cell cycle as evidenced by increased PCNA 
staining and BrdU incorporation, and there is a marked induction of p21 (24).  
Higher levels of p21 are concentrated in the nuclei of distal and proximal tubule 
cells upon cisplatin injury (22).   
 While the mechanism of p21 protection is not fully understood, its role in 
regulation of the cell cycle may be key in repairing and regenerating injured cells 
(22, 24).  Studies using p21 -/- mice have indicated that acute kidney injury- 
associated loss of function is exacerbated and worsened following cisplatin 
administration when compared to wild-type mice (26). Morphologically, cisplatin-
induced AKI damage is restricted to the distal and proximal tubules.  However, 
the damage in knockout mice was present throughout the entire kidney cortex, 
and apoptosis was also more widespread in these mice (22).  Furthermore, there 
was an increase in nuclear size due to polyploid content of proximal tubule cells 
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as the result of an uncoordinated cell cycle, thus indicating the importance of p21 
mediating AKI through cell cycle progression control.  Furthermore, studies have 
also shown that when both p21 and 14-3-3σ (another cell cycle inhibitor protein) 
are expressed together, cell cycle progression is inhibited, resulting in repair of 
damaged cells and subsequent regeneration of healthy epithelial cells(27).    
   Animal knockout studies have been supplemented with in vitro studies.  
p21 overexpression in mouse proximal tubular cells instilled cytoprotective 
effects (27).  Increasing levels of p21 expression as a potential renoprotective 
therapy has also been reported using prior administration of an adenovirus vector 
directing the overexpression of p21 (27). These studies indicate that p21 has 
renoprotective effects in cisplatin-induced AKI.        
  Taken together, these data suggests that upon initial cell stress, 
quiescent cells enter into the cell cycle and cell cycle inhibitors such as p21 and 
14-3-3σ are induced to check the cycle at both G1 and G2 phases(27).  Both p21 
and 14-3-3σ are needed to successfully coordinate the cell cycle so that injury to 
the cell can be properly repaired, and this in turn leads to repair and regeneration 
of renal cells after acute injury (27).                                 
 Most research on cyclin-dependent kinase inhibitors has focused mainly 
on the CIP/KIP family, especially p21.  Little is known about the INK4 family, but 
recent studies have shown that p18 is important.  p18 interacts with CDK4/6 and 
inhibits the cell cycle in early G1 phase (28).  Studies using p18 -/- mice have 
shown, over a course of 28 days, p18 -/- mice have significantly worse survival 
(28).  Furthermore, these mice showed increased markers of endoplasmic 
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reticulum stress (ER stress), and worse injury morphology.  Taken together these 
data indicate that cisplatin-induced AKI was aggravated in p18 -/- mice, and that 
p18 may play a role in protecting the kidney by interaction with ER stress cell 
death pathways (28).  This was confirmed in studies with p18 overexpressing 
LLC-PK1 renal tubular epithelial cells.  Overexpression of p18 in these cells 
inhibited the cell cycle in the G1 phase, and this was associated with a decrease 
in apoptosis levels (29).  Commonly, the ER stress pathway promotes cell 
survival, but in times of prolonged stress (as associated with AKI), the ERS 
pathway favors apoptosis. Thus, it was concluded that p18 protects from 
cisplatin-induced AKI by inhibiting the ER stress pathway and therefore apoptosis 
(29).  
 Activation of inflammatory pathways and immune cell infiltration are also 
involved in cisplatin-induced AKI.  After an acute injury, injured resident kidney 
cells release tumor necrosis factor α (TNFα) which serves as a chemoattractant 
to recruit immune cell types, mainly neutrophils to the site of injury in the kidney 
(30).  Once recruited, neutrophils can initiate the activation of the downstream 
immune system.  Once this activation occurs, M1 subtype macrophages eat 
dead proximal tubule cells and neutrophils (31).  It has been shown that 
recruitment of this type of macrophages amplifies initial injury in the kidney (21). 
While neutrophils and macrophages are involved in the initial inflammatory 
response after injury, many other immune cell types have been reported as 
mediators of cisplatin-induced AKI. Of importance are CD4+ cytotoxic T cells, 
CD4+CD25+ T regulatory cells, and dendritic cells(15).  Of these cells types, the 
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role of CD4+ cytotoxic T cells has been well characterized.  Mice depleted of 
CD4+ cytotoxic T cells had better renal function and less injury when treated with 
cisplatin and when these mice had their CD4+ cytotoxic T cell levels restored, 
renal function decreased and injury worsened(32).  This may have been due to 
the fact that these cells produce FasL and Tim-1 which are important for T-cell 
mediated cytotoxicity, leading to the death of proximal tubule cells (32).    
Whereas CD4+ cytotoxic T cells are detrimental in AKI, CD4+ CD25+ T 
regulatory cells are protective.  These cells play a role in innate immune 
suppression as well as suppression of CD4+ T cell –mediated cytotoxicity (33).  
In animal studies where T regulatory cells were depleted, AKI was worsened 
(34). 
Dendritic cells are anti-inflammatory as evidenced by their production of 
IL-10, an anti-inflammatory cytokine (35).  Furthermore, dendritic cells can induce 
T regulatory cells, suggesting that they are protective in cisplatin-induced AKI 
(36).  This is in fact the case- depletion of dendritic cells resulted in decreased 
renal function, increased tubular injury, and higher mortality rates when mice 
were treated with cisplatin (37). 
Taken together, previous studies suggest that AKI is marked by a very 
complex mechanism of injury.  In addition to cell death, cell cycle arrest, and 
immune cell infiltration, AKI pathophysiology also includes oxidative stress as 
mediated by mitochondrial dysfunction, glutathione depletion and inactivation, 
and endothelial cell dysfunction (7, 15).           
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Most of what is known about cisplatin-induced AKI pathology exists 
because we are able to study these processes in mouse models of AKI.  As a 
result, studies for the development of therapies for protection against AKI and 
reversing injury as the result of AKI have also been performed in animal models.  
Unfortunately, while there have been many experimental therapies developed for 
the treatment of cisplatin-induced AKI, none have made it past clinical trials (7, 
15).  Currently, only palliative care therapies exist for severe, sustained AKI (1, 3, 
4).   In order to prevent cisplatin-induced AKI in patients, several precautions are 
taken.  When possible, lower doses of cisplatin are used in conjunction with 
newer, less toxic chemotherapeutics to minimize cisplatin nephrotoxicity while 
maintaining its therapeutic efficacy(38).  However, this type of dosing regimen is 
usually only used for palliative care.  In instances where cisplatin can be used to 
cure cancer, particularly in the case of germ cell line cancers, a high dose of 
cisplatin administered over a short period of time is still used, putting these 
patients at the highest risk for developing AKI (38).  Currently, the standard 
preventative measure for cisplatin nephrotoxicity and subsequent AKI is 
intravaneous saline infusions given before cisplatin administration.  Saline 
induces diuresis, and by doing so, lowers overall nephrotoxicity, but the 
mechanism by which saline is preventative is not well-defined (38).    
Alternatively, the administration of less nephrotoxic platinum drugs may be 
given to patients who run a high risk of developing AKI.  Of the platinum 
alternatives, carboplatin is commonly used.  Carboplatin was designed 
specifically to reduce the side effects of cisplatin (39, 40).  Unfortunately, 
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carboplatin can still have nephrotoxic side effects, especially in patients who 
have previously received cisplatin and have increased nephrotoxicity sensitivity 
(41).  Furthermore, cisplatin is still the better of drug of choice for most cancers 
due to its higher potency (39). 
An alternative to creating a new, less nephrotoxic platinum 
chemotherapeutic would be to design a drug that could be used to protect the 
kidney from injury during the course of cisplatin treatment.  This would not only 
avoid the development of AKI, but also allow for higher doses of cisplatin to be 
administered, which would make for a more efficacious cancer treatment option.  
Unfortunately, there is only one renoprotective agent available for cisplatin-
induced AKI, and it is no longer used clinically for this purpose (42).  In the early 
2000’s, amifostine was FDA-approved to be used as a renoprotective agent with 
cisplatin treatment of ovarian cancer (43).  In a Phase III clinical trial of women 
with ovarian cancer, amifostine lowered the risk of nephrotoxicity from 33% to 
10% overall, and the percentage of patients that required a delay in the next 
treatment or discontinuation of treatment altogether due to nephrotoxicity 
decreased from 36% to 10% (43, 44).   
High doses can be given due to amifostine’s mechanism of action, thereby 
increasing its efficacy as a renoprotective agent.  Amifostine is rapidly converted 
to an active thiol metabolite via dephosphorylation by alkaline phosphatase.  This 
thiol metabolite is preferentially taken up by normal tissue (42).  Once uptake 
occurs, this active thiol metabolite scavenges for free radicals and depletes them.  
At the same time, it can also bind directly to cytotoxic drug molecules to 
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inactivate them (42).  Furthermore, amifostine has few side effects, most of which 
are reversible and manageable.  The most serious side effects include transient 
hypotension, allergic skin reactions, and severe nausea(42).  Most importantly, 
amifostine doesn’t attenuate the efficacy of chemotherapeutics.  In fact, pre-
clinical studies have suggested that amifostine may protect against the 
development of secondary malignancies associated with chemotherapeutic 
treatment (42) 
While extensive pharmacokinetics have been studied in mice, little is 
known about the pharmacokinetics of amifostine in humans.  Most clinical trials 
done with amifostine and cisplatin use a single, high dose of amifostine given 
before a single dose of cisplatin (38).  Furthermore, the dose of cisplatin used is 
usually very high.  Currently, most cisplatin regimens consist of lower doses of 
the drug given over an extended period of time, or in multiple doses to curtail 
nephrotoxic side effects.  Thus the efficacy of amifostine with these newer low 
dosing regimens has yet to be elucidated.  Case studies have reported that 
amifostine given before treatment of ovarian cancer with cisplatin and etoposide 
can lead to severe nephrotoxicity, ototoxicity, and neurotoxicity(45).  Due to lack 
of renoprotective and injury ameliorating therapeutics available, nephrotoxicity of 
cisplatin must be monitored closely.  This is done by extensively measuring 
changes in kidney function.  Clinically, the golden standard is measurements of 
GFR and changes in serum creatinine (46-49).  Serum creatinine is used as an 
indirect measure of GFR, as a doubling in serum creatinine equates a 50% 
decrease in GFR (loss of kidney function).  Unfortunately, measuring serum 
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creatinine levels is an insensitive and faulty assay(49).  Changes in serum 
creatinine usually are not detectable until there is 50% nephron loss.  At this 
point, the level of AKI sustained is very high and may not be reversible.  
Furthermore, serum creatinine levels can be altered by levels of protein uptake 
and changes in protein in catabolism (47-49).  This is due to the fact that 
creatinine is the byproduct of creatine breakdown from muscle catabolism.  Thus, 
basal serum creatinine levels differ based on age and weight (47-49).  These 
factors may falsely represent a full recovery from AKI, but rather suggest that 
there is injury/ change in kidney function, but that it is undetectable by this 
method.  
 This may be key in explaining why, even in patients with one instance of 
AKI in their lifetime, there is increased susceptibility to developing chronic kidney 
disease later in life (50-52).   There are approximately 600,000 new cases of AKI 
each year, and it has been suggested that 20% of these cases go on to develop 
CKD (51, 53).  This 20% accounts for patients who sustain severe AKI requiring 
dialysis and are able to recover.  Patients who receive an acute tubular necrosis 
diagnosis go on to develop CKD 18-24 months later (50).  This is surprising as it 
was formerly believed that patients who recovered from AKI had generally good 
renal outcomes.  However, studies on AKI recovery used the development of 
end-stage renal disease to define a poor renal outcome.  Studies including the 
progression of AKI to CKD indicate that the poor prognosis rate of patients who 
“recover” from AKI is actually greater than expected (50).  Furthermore, the 
likelihood of developing CKD is also associated with the number of times a 
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person sustains AKI in their life (54).  Thus, there is a need to monitor kidney 
function even after recovery. 
     Chronic disease kidney refers to a kidney disorder of varying severity, and 
thus affects many people (55).  Chronic kidney disease is a progressive disease, 
and the early stages are often asymptomatic and reversible.  However, the 
problem with chronic kidney disease arises from the worsening of the disease 
over the period of many decades (55).  As a result, it is obvious that chronic 
kidney disease is often associated with aging (56).  This is in part due to the fact 
that in older populations, there is an increased prevalence of diabetes and 
hypertension (56).  These comorbidities worsen chronic kidney disease.  
Ultimately, a patient who has chronic kidney disease and one or more 
comorbidities are more likely to progress from chronic kidney disease to end-
stage renal disease (55). Much like AKI, there are currently no therapies to 
ameliorate chronic kidney disease or halt progression to end stage renal disease.  
As a result, most patients will be placed on dialysis, which is costly and is often 
not that useful.  Eventually, the kidney failure worsens, leading to high rates of 
mortality.  There are approximately 400 per million people deaths in the U.S. 
from chronic kidney disease alone (55).  
Clinically, CKD is defined as the presence of kidney damage, particularly 
albuminuria and proteinuria, and decreased kidney function as measured by 
serum creatinine levels for a period of three months or more (55).  The severity of 
this disease is classified based on the total loss of GFR, as is the case for AKI as 
well.  The pathology of chronic kidney disease differs from that of AKI.  Whereas 
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proximal tubule cells are the source of most damage in AKI, glomeruloclerosis 
and nephrosclerosis are commonly associated with chronic kidney disease (55).  
Furthermore, chronic kidney disease is marked by an increase in interstitial 
kidney fibrosis.  Fibrosis is the hallmark of CKD, and is characterized by the 
pathological deposition of excessive extracellular matrix (57).   This matrix is 
often rich in collagens type I and III, as well as fibronectin (58, 59).  In the 
presence of fibrosis, tubule cells cannot secrete toxins or receive nutrients from 
circulation due to the separation from peritubular capillaries by fibrosis (57).  The 
processes that underlie fibrosis are similar to those that occur in normal wound 
healing.  Whereas in wound healing myofibroblasts play a beneficial role, the 
persistence of this cell type results in detrimental processes indicative of 
fibrogenesis (57).   
 Myofibroblasts are the cell type most responsible for the production of 
cytokines and chemokines leading to increase deposition of extracellular matrix 
proteins, particularly collagens (57).  Under normal conditions, myofibroblasts are 
not detectable in the kidney.  During pathogenic processes, these myofibroblasts 
are found to increase greatly in number and are found usually in the interstitium 
and around injured glomeruli, where fibrosis most commonly occurs (57).  The 
source of these myofibroblasts is still a matter of debate.  Intricate fate-mapping 
studies have shown that a small percentage of myofibroblasts arise from resident 
fibroblasts in the kidney, while most are derived from pericytes (57) .   
 Immune cells, particularly macrophages, play a pivotal role in resolving 
fibrogenesis.  This is due to the fact that macrophages are able to internalize 
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collagen and degrade it with MMPs (60) .  Once degraded, collagen can then be 
further destroyed by cathepsins and lysosomes (60).  In doing so, these 
macrophages can ameliorate low levels of fibrosis.  Currently, available animal 
models to study chronic kidney disease focus on this fibrotic aspect and 
developing therapies to ameliorate fibrosis.  These models include the UUO, IR, 
and folic acid models (61).   
As previously discussed, AKI is associated with an increased likelihood of 
developing chronic kidney disease based on severity and the number of AKI 
occurrences (50).  However, recent studies have suggested that AKI can 
progress to CKD, and that AKI and CKD are interconnected syndromes (62).  
The process by which this AKI to CKD transition occurs is very complex, but 
focuses on the underlying mechanism of maladaptive repair.  To understand the 
processes that occur during maladaptive repair, it is first important to understand 
the processes involved in adaptive repair.     
After AKI, neutrophils are responsible for the activation of the immune 
system and recruit M1 type macrophages to the site of injury (15, 21).  While M1 
macrophages have been associated with worsening of injury, M1 macrophages 
quickly take on a M2 phenotype, which is essential for adaptive repair (63, 64).  
These M2 macrophages remove cellular debris and secrete TGFβ, fibronectin, 
and other growth factors that are essential for supporting the growth of new 
epithelial cells to replace those that have undergone apoptosis or necrosis (63, 
64).  The source of these new epithelial cells has been extensively studied, and 
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data suggest that these cells arise from existing epithelial cells which are able to 
dedifferentiate and proliferate to replace lost cells (21, 57).   
There are several overlapping processes that define adaptive and 
maladaptive repair.  The true difference between these forms of repair depends 
on whether or not the injury is singular (as is often the case with AKI), or if it is 
recurrent.  Grgic et al. developed a Six2-Cre-LoxP technology to selectively 
express the diphtheria toxin receptor in proximal tubule cells (65).  Using this 
model, they showed that a tubule cells are able to repair injury from a single dose 
of diphtheria toxin (65).  However, after three doses of the toxin, persistent 
inflammation ensued, leading to increased levels of TGFβ1, collagen Type 1a1 
(col1a1), and fibronectin (65).  This ultimately resulted in progressive 
fibrogenesis and secondary glomerulosclerosis, indicative of CKD (65).   
To better understand the processes occurring with recurrent injury, 
maladaptive repair in terms of both the cell cycle of tubular epithelial cells and the 
role of immune cells, particularly macrophages, has been extensively studied in 
the context of CKD.  In several models of CKD, it has been shown that cells often 
become senescent, and Grgic et al. have hypothesized that senescence may 
play a pivotal role in maladaptive repair associated with recurrent injury (65).  
Senescence is a detrimental process for two reasons.  For one, senescent cells 
will remain present in the kidney and cannot be cleared by recruited 
macrophages.  Thus, they cannot be replaced with new epithelial cells. 
Ultimately, this results in a decline in kidney function that is permanent.  
Secondly, even in this senescent state, epithelial cells continue to produce pro-
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fibrotic factors, thus increasing fibrogenesis (21, 66).  Yang et al. demonstrated 
that this senescent state was the result of G2/M cell cycle arrest in these 
epithelial cells (66).   
Furthermore, it has been shown that recruited M1 macrophages are 
unable to undergo the switch to M2 type macrophages, thereby leading to 
maladaptive repair and worsened injury (67).  While M2 subtype macrophages 
are regarded as protective against maladaptive repair, recent studies have 
suggested that M2 macrophages can also be key in fibrogenesis (68).  When 
present at high levels in a unilateral ureteral obstruction model, M2 macrophages 
produce large amounts of TGFβ, which is an inducer of fibrotic pathways (68).  
When M2 macrophages were depleted in this model, fibrosis was ameliorated 
(68).  Ultimately, maladaptive repair mechanisms are associated with recurrent, 
persistent injury and models of CKD.  Of maladaptive repair mechanisms, cell 
cycle arrest and the role of both M1 and M2 macrophages have been shown to 
play a role in kidney fibrosis. 
With the increasing prevalence of CKD and more studies are emerging on 
the importance of the AKI to CKD transition/ recurrent injury, it is important to have 
animal models that can be used to recapitulate the process by which this happens.  
This is especially true for cisplatin-induced AKI, as approximately 10-20% of all 
cancer patients will receive cisplatin alone or in combination therapy, and 33% of 
these run the risk of developing AKI. Furthermore, most of what is known about 
maladaptive repair involved in AKI to CKD transition has been studied in 
ischemia/reperfusion models of AKI.  Unfortunately, no such models exist for 
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cisplatin-induced AKI leading to CKD.  Furthermore, the standard model of 
cisplatin-induced AKI does not recapitulate the type of treatment regimen patients 
receive and does not allow for long-term studies.  With the standard model of AKI, 
mice are administered a single, high dose of cisplatin (>20 mg/kg).  This dose is 
lethal to the mouse beyond 72 hours, and thus examining the AKI to CKD 
transition, a process that may take place over several decades in humans, is not 
possible.  Furthermore, humans receive multiple low doses of cisplatin.  This is 
done to decrease the likelihood of AKI while maintaining a dose that is efficacious 
for the treatment of the cancer.  
Thus, we have developed a low dose, repeated dosing model of cisplatin 
induced kidney injury that both recapitulates the type of dosing regimen patients 
receive, as well as allows for long-term analyses of what happens to the kidneys 
post-AKI.  We have found that with this model, processes indicative of AKI such 
as high levels of cell death do not occur, but that the ultimate pathological outcome 
is fibrosis.  Thus, this model can be used to examine the transition from AKI to 
CKD in a mechanistic way.  In doing so, this will provide insight into when 
maladaptive repair occurs temporally and if processes that occur in this model are 
similar to those seen in models of CKD.  By understanding more about what 
happens in this transition mechanistically, this will provide insight into possible 






MATERIALS AND METHODS 
Reagents and Antibodies 
The following antibodies were purchased from Cell Signaling (Beverly, MA) unless 
otherwise noted: Cleaved Caspase 3 (#9664), C/EBP homologous protein (CHOP; 
#2895), c-Jun N terminal kinases (JNK; #9258), p-JNK (#4668), transforming 
growth factor β (TGF-β; #3712S), fibronectin (F3648, Sigma-Aldrich, St. Louis, 
MO), phospho- Mothers against decapentaplegic homolog 3 (pSMAD3; #12747), 
α-tubulin (Santa Cruz, Dallas, TX, SC-23948) and β-actin (Santa Cruz, SC-47778). 
Cisplatin (P4394, Sigma Aldrich, St. Louis, MO) was used for experiments 
comparing the effects of a high, single dose model (euthanized three days later) 
with the new repeated dosing model.   Pharmaceutical grade cisplatin (purchased 
directly from the University of Louisville hospital pharmacy) was used for 
experiments comparing the effects of single versus repeated injury from cisplatin. 
Similar effects were observed for both sources of cisplatin. 
Animals 
FVB mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  All 
mice were maintained on a 12-hour light/12-hour dark cycle and provided food and 
water ad libitum. Animals were maintained under standard laboratory conditions. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Louisville and followed the guidelines of the
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 American Veterinary Medical Association.  Cisplatin at 25 mg/kg in PBS (200 
μL/animal) was administered by i.p. injection.  Seventy-two hours after cisplatin 
injection, these mice were euthanized.  Another cohort of mice received either 7 or 
9 mg/kg cisplatin in PBS administered by i.p. injection once a week for four weeks.  
For these survival studies, mice were monitored for weight loss and signs of 
discomfort/distress on a daily basis.  Mice exhibiting a weight loss of 20% or more 
total body weight or high levels of discomfort and stress were euthanized.  Mice 
that survived the course of treatment were sacrificed 72 h after the fourth injection 
of cisplatin. Serum was prepared and stored at -80°C. The kidneys were flash 
frozen in liquid nitrogen or fixed in 10 % neutral buffered formalin for histological 
purposes.  
Blood Urea Nitrogen (BUN) and Serum Creatinine (SCr) Determination 
BUN (DIUR-500) and SCr (C7548-120) were determined using kits from Bioassay 
Systems (Hayward, CA) and Point Scientific Inc. (Canton, MI), respectively 
following the manufacturers’ instructions.  For SCr, this specific assay kit employs 
a two reagent enzymatic assay system to eliminate interference by endogenous 
creatine and ascorbic acid.  
Protein Quantification, Western Blot Analysis, and ELISAs 
Homogenates were made from kidney cortex by homogenization in Cell Extraction 
Buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl,1 mM imidazole, 1 mM magnesium 
acetate, 20 mM EGTA, 10 mM  β-mercaptoethanol) containing a Complete 
Protease Inhibitor Cocktail Tablet and Phosphatase Inhibitor Cocktail Tablet 
(Roche, Indianapolis, IN). Homogenates were centrifuged at 15,000 X g for 10 
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minutes at 4° C.  Supernatants were removed, vortexed, aliquoted, and stored at 
-80°C until use. Protein concentrations were determined using Bradford Reagent 
(Bio-Rad, Hercules CA). Kidney homogenate (40 μg) was separated on 4–12% 
gradient tris-glycine-SDS polyacrylamide gels and transferred to PVDF 
membranes that were blocked in 5% (w/v) dried milk in tris-buffered saline 
containing 0.1% Tween-20 (TBST) for 15 minutes. Membranes were incubated 
with 1:5000 dilutions of primary antibody overnight at 4°C. The next morning, 
membranes were washed 3 times for 5 minutes each with TBST containing 5 % 
(w/v) dried milk. After incubation for 1 hour at room temperature with secondary 
antibodies conjugated with horseradish peroxidase (1:40,000 in TBST containing 
1.25% (w/v) dried milk), membrane proteins were detected by chemiluminiscence 
substrate. ELISAs for KIM-1 (DY1817, R&D systems, Minneapolis, MN) and NGAL 
(DY1857 R&D Systems) were performed on the urine as directed by the 
manufacturer. 
Gene Expression 
Total RNA was isolated using RNA-STAT 60 (TEL-TEST Inc., Friendswood, TX) 
combined with mini bead-beater glass beads and a Mini Bead Beater machine 
(Cole-Palmer, Vernon Hills, IL).  Other than using the bead beater glass beads to 
disrupt the tissue, the protocol provided by TEL-TEST was used.   cDNA was made 
from 1 µg of total RNA using High Capacity Reverse Transcriptase (Life 
Technologies, Grand Island NY) following manufacturers’ instructions.  Gene 
specific cDNAs were quantitated using real-time PCR using predesigned TaqMan 
assays. Tumor necrosis factor-alpha (TNF-α, Mm00443258_m1), interleukin-6 
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(IL6; Mm00446190_m1), interleukin 1-beta (IL1E; Mm0043228_m1), chemokine 
ligand (c-x-c motif) 1 (CXCL1; Mm04207460_m1), monocyte chemotactic protein-
1 (MCP-1; Mm00441242_m1), plasminogen activator inhibitor-1 (PAI-1; 
Mm00435860_m1), alpha- smooth muscle actin (α-SMA ; Mm1546133_m1), bone 
morphogenetic protein-7 (BMP-7; Mm00432102_m1), collagen type 4a1; ( 
COL4a1; Mm01210125_m1), cyclin dependent kinase inhibitor 2a (Cdkn2a; 
Mm00491449-m1), connective tissuse growth factor (CTGF; Mm01192932_g1), 
collagen type 1a1 (Col1a1; Mm00801666_g1), and the normalization genes beta 
2 microglobulin (B2M; Mm00437762_m1) and β-actin (Mm01205647-g1) were 
purchased from Life Technologies (Grand Island NY) and used in combination with 
2X Gene expression Master Mix (Life Technologies).  
Histology 
Kidney sections (5 microns thick) from cisplatin-treated and untreated animals 
were stained with H&E and PAS, and the degree of morphologic changes was 
determined by light microscopy in a blinded fashion by a renal pathologist. The 
following measures were chosen as an indication of morphologic damage to the 
kidney after treatment with vehicle or cisplatin: proximal tubular necrosis, loss of 
brush border, proximal tubule degradation, tubular casts, presence of inflammatory 
cells, and interstitial fibrosis   These measures were evaluated on a scale from 0 
to 4, which ranged from not present (0), mild (1), moderate (2), severe (3), and 




Kidney sections (5 microns thick) were rehydrated in Histoclear followed by an 
ethanol gradient. Antigen retrieval was performed in citric acid buffer pH 6.0 at 
95°C in a steamer for 30 min. Endogenous peroxidases were inhibited with 3% 
hydrogen peroxide and dual endogenous enzyme blocker (Dako, S2003) for 10 
minutes, followed by two 5 minute PBS washes.   Slides were then blocked with 
avidin for 10 minutes followed by a PBS wash, and then biotin for 10 minutes 
followed by another wash in PBS (Dako, X0590). Slides were further blocked with 
5% normal goat serum in 0.1% TBST for 1 hour at room temperature.  α-SMA 
primary rabbit antibody (Abcam, ab5694) was added to slides at a concentration 
of 0.5 µg/mL, and allowed to incubate at 4°C overnight.   Biotinylated goat anti-
rabbit IgG antibody (1:25000) (Vector laboratories, BA-1000) was added to each 
section and incubated for 30 minutes at room temperature. Slides were rinsed 
twice with PBS for 5 minutes each. Vector ABC reagent (Vector laboratories, PK-
7100) was added to each section and incubated for 30 minutes at room 
temperature. Slides were rinsed 2 times with PBS for 5 minutes each, followed by 
the addition of NovaRed Substrate to detect HRP (Vector Laboratories, SK-4800) 
to each section for 5-7 minutes. Slides were rinsed in distilled water for 5 minutes, 
counterstained with modified Mayer’s hematoxylin (Thermo-scientific, 72804), then 
dehydrated in an ethanol gradient to Histoclear, followed by mounting with 
Permount (Fisher Scientific, SP15).  Positive staining for α-SMA was quantified 
using Metamorph Image Analysis software, and percent positive pixels were 
calculated as follows: (threshold area/(total area-acellular area)).  
Sirius Red/ Fast Green Staining 
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Kidney sections (5 microns thick) were rehydrated in Histoclear followed by an 
ethanol gradient.  Slides were then dipped into a Coplin jar containing PBS-T 
(PBS+0.1% tween-20) and incubated for 5 minutes. Slides were washed with 
distilled water twice for 5 minutes each and then incubated in saturated picric acid 
(1.2% w/v, Ricca Chemicals; 5860-32) containing 0.1% Sirius Red (Sigma, 
365548) and 0.1% Fast Green (Sigma, F7258).  Slides were washed with 5% 
glacial acetic water until water ran clear.  Tissue samples were then dehydrated 
and fixed using Permount (Fisher, F-SP15-100).  Positive staining for Sirius Red 
was quantified using Metamorph Image Analysis software, and percent positive 
pixels were calculated as follows: (threshold area/(total area-acellular area)). 
Statistical Analysis Data  
Data are expressed as means ± SEM for all experiments. Multiple comparisons of 
normally distributed data were analyzed by one-way ANOVA, as appropriate, and 
group means were compared using Tukey post-tests. Single comparisons were 
analyzed by Student’s t-test where appropriate. The criterion for statistical 
differences was p < 0.05*, p<0.01** and p<0.001***.  For statistical analysis of the 









Effects of dosing regimens on mouse survival.  The current, standard model 
used to study cisplatin-induced AKI does not allow for the analysis of long-term 
effects on kidney function and physiology, nor does it recapitulate the repeated 
dosing regimen of cisplatin patients receive in the clinic. We hypothesized that 
administration of a low dose of cisplatin once a week for several weeks, which 
better recapitulates the human dosing regimen, would improve mouse lifespan, 
thus allowing for analysis of long-term effects on kidney function and physiology. 
We compared survival of mice given a single high dose of cisplatin (standard 
dosing model; 25 mg/kg) to mice given a dose of cisplatin (7 or 9 mg/kg) once a 
week for 4 weeks.  All mice subjected to the standard dosing regimen were 
sacrificed three days after cisplatin injection due to moribund status.  Mice treated 
with the 7 mg/kg repeated dosing regimen survived the course of treatment and 
were sacrificed 3 days after the fourth treatment (day 24). Ninety percent of mice 
treated with a 9 mg/kg repeated dosing regimen survived until day 24 (Fig1). These 
data indicate that the repeated dosing model with 7 mg/kg enables longer-term 

















Effects of dosing regimens on kidney injury and function. In order to assess 
the impact of repeated, low dosing of cisplatin on the kidney, we measured 
markers of kidney function and injury in the serum and urine of mice, respectively. 
Blood urea nitrogen (BUN) and serum creatinine (SCr) are standard measures of 
kidney function as their levels increase in the blood when the filtering capacity of 
the kidney is significantly reduced (69). BUN levels of mice treated with the 
standard dosing model were significantly increased at 72 hours post-treatment 
(Fig2A).  In the repeated dosing model, BUN also increased, but not significantly 
(Fig2A). SCr levels were significantly increased for both the repeated and standard 
dosing models, but SCr levels were higher in the standard dosing model (Fig2A). 
Kidney injury was evaluated by levels of urinary KIM-1 and NGAL, sensitive 
biomarkers of AKI (70, 71). Urinary KIM-1 and NGAL levels were significantly 
increased in the standard dosing model, but only NGAL levels were significantly 
increased in the repeated dosing model, albeit to a lesser extent than in the 
standard model (Fig 2B). These data indicate that the repeated dosing model of 
cisplatin causes less loss of kidney function and less kidney injury than the 













Effects of dosing regimen on inflammatory cytokine and chemokine levels.  
One of the components of the standard dosing model of AKI is a large 
inflammatory response.  We compared the levels of inflammatory cytokines and 
chemokines between the standard and repeated dosing models. TNFα is a 
potent cytokine that mediates inflammatory tissue damage in the kidney, and 
activates downstream cytokines and chemokines, particularly IL1-β, MCP-1, and 
IL-6 (4, 72).  CXCL1 plays a role in neutrophil recruitment to sites of tissue 
inflammation (73).  mRNA levels of Tnfα, Il1-β, Mcp-1, and Cxcl1 were increased 
significantly and approximately to the same extent in both the standard and 
repeated dosing models (Fig3A, C, D, E).  Il-6 mRNA was significantly increased 
in the standard dosing model, but only increased 5.51±2.01-fold in the repeated 
dosing model (Fig3B).  These data suggest similar effects of dosing on activation 














Effect of dosing regimen on activation of ER stress and cell death proteins. 
Cell death and ER stress are characteristic of cisplatin-induced AKI and 
inhibiting/deleting key players in apoptosis protects the kidney from cisplatin in the 
standard dosing model (7, 74, 75).  Therefore, we assessed cellular markers of ER 
stress and cell death proteins in both models.  JNK phosphorylation and activation 
is associated with ER stress-induced apoptosis and G2/M cell cycle arrest (15, 66).  
We found that JNK was phosphorylated and activated in both models (Fig4). 
CHOP is also associated with ER stress, and was also activated in both models 
(Fig4) (76).  However, cleaved caspase 3 (CC3), a marker of apoptosis, didn’t 
show an increase in the repeated dosing model.  (Fig4).  These data suggest that 
while both models show similar trends in activation of ER stress proteins, there is 



























Effect of dosing regimen evident in tissue pathology. The standard dosing 
model of cisplatin-induced AKI is associated with changes in kidney pathology, 
particularly with increased levels of tubular necrosis and loss of brush borders (21, 
77).  We compared kidney pathology of the standard and repeated dosing models 
and examined tubular necrosis, loss of brush borders, tubule dilation, cast 
formation, presence of inflammatory cells and interstitial fibrosis, all of which are 
indicative of kidney injury and damage.  Blinded analysis by a certified pathologist 
indicated tubular necrosis was significantly higher in the standard dosing model, 
compared to the repeated dosing model (Fig5A).  In contrast, there was a 
significant loss of brush borders (Fig5B), an increase in tubular dilation (Fig5C), 
and an increase in cast formation (Fig5D) in both models. Interestingly, only the 
repeated dosing model displayed a significant increase in the presence of 
inflammatory cells and interstitial fibrosis (Fig5E,F). These data demonstrate that 















Fibrotic markers and fibrosis in the repeated dosing model.  Since pathology 
of kidney sections revealed tubulointerstitial fibrosis in the repeated dosing model, 
we wanted to examine known markers of maladaptive repair involved in the 
induction of fibrosis.  TGF-β is released by immune cells in response to kidney 
injury as a way to make conditions suitable for new epithelial cells to grow (22).  
However, during maladaptive repair, dedifferentiated epithelial cells in a senescent 
state can also release TGF- β, leading to fibrosis (21).  TGF-β can signal through 
its receptor to lead to phosphorylation of SMAD3, thereby activating pathways that 
increase extracellular matrix protein deposition, particularly fibronectin (78, 79).  
BMP-7 is also a member of the TGF-β superfamily and works to counteract the 
profibrotic activity of TGF-β (80).  TGF-β, p-SMAD3, and fibronectin were all 
increased at the protein level in the repeated dosing model (Fig6A).  Bmp-7 mRNA 
expression was significantly decreased (Fig6B).  Col1a1, which encodes for 
collagen type I protein and is a transcript marker of fibrosis, also significantly 
increased at the message level in the repeated dosing model (81)(Fig6B).  PAI-1 
is associated with maladaptive repair and is produced by resident and intrarenal 
inflammatory cells and inhibits fibrinolysis, leading to the accumulation of scar 
tissue in the kidney (82). Pai-1 mRNA expression was increased in the repeated 
dosing model (Fig6B).  Cdkn2a encodes for p16, and increased expression of 
Cdkn2a is associated with maladaptive repair and cell cycle arrest at the G2/M 
phase (66); Cdkn2a expression was significantly increased following repeated 
dosing (Fig6B).  Myofibroblast numbers increase during kidney fibrosis and are 
responsible for synthesis of collagen (83, 84).  These cells can be identified by 
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their expression of α-SMA.  α-SMA IHC indicated increased numbers of 
myofibroblasts following repeated dosing of cisplatin (Fig6D).  Collagen deposition 
as the result of extracellular matrix production can be quantified with Sirius red, 
fast green staining (SR/FG) which stains collagen red.  We performed SR/FG 
staining and found that collagen levels increased in the kidneys following repeated 
dosing of cisplatin (Fig6C). Taken together, these data indicate that there are 
alterations in key mediators of kidney fibrosis in the repeated dosing model, 
indicative of maladaptive repair.  Furthermore, since fibrosis is the hallmark of 
CKD, these data suggest that the ultimate outcome of our repeated, low dosing 



















Comparison of a single, low dose of cisplatin (7VVV) to repeated dosing 
model. To determine if fibrosis is a result of a single, low dose of cisplatin, or rather 
repeated injury from several low doses, mice were administered a low dose of 
cisplatin (7 mg/kg) followed by three weekly vehicle injections (7VVV) and 
compared to mice receiving 4 weekly cisplatin injections (7777).  BUN and SCr 
both increased significantly in the repeated dosing model, but not following a single 
low dose (Fig7A).  Likewise, levels of Tnfα and Il6 mRNA expression increased 
with repeated dosing (7777) of cisplatin, but not following a single dose (7VVV; 
Fig7C). Western blot analysis of TGF-β and fibronectin in the kidney indicated that 
a single dose was not sufficient to cause an increase in these fibrotic markers 
(Fig7B).  mRNA expression of Pai-1, Cdk2na, and Col1a1 did not increase, and 
Bmp-7 mRNA levels did not decrease in the single, low dose regimen (Fig7C).  
Quantification of SR/FG staining for collagen deposition and IHC staining for α-
SMA for myofibroblasts also indicated that a single low dose was insufficient to 
elicit changes (Fig7D,E). These data suggest that fibrosis is a result of repeated 
injury to the kidney by several low doses of cisplatin. 














The dosing regimen of cisplatin varies by cancer type as well as the ability 
of the patient to handle prescribed doses.  In lung cancer, for example, patients 
receive 60-100 mg/m2 of cisplatin intravaneously every 21 days in conjunction with 
other antineoplastic drugs, while patients with cervical cancer receive 40 mg/m2 of 
cisplatin intravaneously once a week for six weeks in conjunction with radiation 
therapy (85).  Regardless, treatment of human cancers with cisplatin often leads 
to a nephrotoxic effect that is cumulative and dependent on the dose of cisplatin 
being administered.  AKI occurs in some individuals even after one low dose of 
cisplatin, and when AKI occurs, oncologists will dramatically lower the dose of 
cisplatin used- usually decreasing the dose by 50-75% (85).  As a result, this leads 
to a less efficacious cancer treatment.  Thus, the development of renoprotective 
agents would greatly aid in allowing patients to receive the full dose of cisplatin for 
a more efficacious treatment, while at the same time decreasing the likelihood of 
an AKI event.  This area of research has been ongoing for thirty or more years.  
Unfortunately with the exception of amifostine, which is no longer used as a 
renoprotective agent in the clinic, there are no renoprotective agents available and 
none have succeeded in clinical trials.  This is in opposition to the fact that many 
renoprotective agents have been tested in rats and mice and have shown a 




Furthermore, it is established that multiple episodes of AKI can lead to CKD 
(51).  This is of importance as, until recently, it was widely held that patients who 
suffer from an episode of AKI usually undergo full recovery.  This is a biased view 
as the standard measure of kidney function in the clinic is SCr, which is highly 
unreliable and can only detect changes in function when there is fifty percent 
nephron loss.  
 In an ideal situation, researchers would be able to study the long-term 
effects of cisplatin-induced AKI in a model that recapitulates a dosing regimen 
similar to what is used in humans- mainly the fact that patients receive multiple 
doses of cisplatin over an extended period of time.  Unfortunately, there are no 
models to study this.  Currently, the standard dosing model of cisplatin-induced 
AKI has limitations that cannot be overcome for studying AKI to CKD progression.  
For one, a single, high dose regimen is not clinically relevant.  Patients are 
administered multiple low doses of cisplatin over an extended period of time.  
Secondly, with the standard dosing model, mice cannot be aged out to study long-
term effects associated with repeated AKI, namely fibrosis—the underlying 
pathology of CKD (86).  Furthermore, models of CKD, which often lead to fibrosis, 
often are short term models that lead to this pathology within a week (i.e. UUO/ IR 
models), and there no models of cisplatin-induced CKD.  Here, we report a new 
model for studying the nephrotoxic effects of cisplatin that mimics the repeated 
administration of cisplatin given clinically, and allows for analysis of long-term 
effects on kidney function. Data obtained from this model indicate that repeated 
cisplatin injury induces interstitial fibrosis which is indicative of CKD, and suggests 
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that targeting fibrotic mediators may prevent both short- and long-term renal side-
effects of cisplatin.  
The standard dosing model of cisplatin induces high levels of kidney injury 
and cell death through apoptosis and necrosis, which are processes known to be 
involved in AKI (7).  This in turn results in a rapid loss of kidney function.  With the 
repeated dosing model, cleaved caspase 3 as a measure of apoptosis is low, and 
pathology reveals a low level of tubular necrosis.  This coincides with lower injury 
levels and a smaller decline in overall kidney function.  These lower levels of injury 
and the maintenance of kidney function with the repeated dosing model may be 
key to explaining how mice treated with multiple low doses of cisplatin are able to 
survive for 24 days, and beyond that.   
As opposed to cell death, the repeated dosing model of cisplatin induces 
interstitial fibrosis.  Fibrosis is regarded as the result of maladaptive repair, which 
is marked by prominent inflammation, G2/M cell cycle arrest leading to cellular 
senescence, and the continual release of growth factors by epithelial cells that 
ultimately culminate in fibrosis (21, 65, 66).  While inflammation is also indicated 
in AKI, it is associated with adaptive repair, and is usually short-lived.  In 
maladaptive repair, however, inflammation persists and is marked by the inability 
of M1 macrophages to become M2-type (36).  M1 macrophages are highly 
associated with worsening of kidney injury, and thus suggests that the persistence 
of this cell type is something that needs to be further examined within our model.  
As far as inflammatory cytokines and chemokines, both models show a similar 
activation of TNFα and its downstream targets, with the exception of IL6.  In the 
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repeated dosing model, IL6 was not significantly elevated.  Although the role of IL6 
in kidney injury is not well understood, it is correlated with onset and severity of 
AKI, and has been indicated as a potential urinary and plasma biomarker of AKI 
(87-89). The differential of IL6 elevation between a high injury model (standard AKI 
model), and a low injury model (repeated dosing model) provides further validity of 
the sensitivity of IL6. 
In AKI, p21 and p53 play major roles in the adaptive processes after injury 
(18, 22, 26, 90).  p21 is responsible for cell cycle arrest before S phase, so that 
damage to injured proximal tubule cells can be repaired before proceeding through 
the cell cycle, while p53 mediates apoptosis (15, 22).  These processes are pivotal 
in removing injured epithelial and tubule cells, and also allowing for the growth of 
new, fully functioning ones to restore kidney function.  In maladaptive repair, p16 
mediation leads to cellular senescence as opposed to apoptosis.  This is mediated 
by G2/M cell cycle arrest (65).  Grgic et al. have shown in a model of diphtheria 
toxin receptor expression on proximal tubule cells leading to PTC only injury,  that 
kidney function can be recovered after a single round of injury induced by 
diphtheria toxin (65). In contrast, recurrent injury resulted in persistent 
inflammation, cellular senescence, and G2/M cell cycle arrest of the tubule 
epithelial cells, which led to maladaptive repair and interstitial fibrosis (65).  G2/M 
arrest and cellular senescence leading to maladaptive repair and fibrosis have also 
been indicated in the ischemia-reperfusion and unilateral ureteral obstruction 
mouse models (66).  G2/M arrest is also associated with an increase in JNK 
phosphorylation (66).  However, JNK has also been indicated as a mediator of cell 
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death as well.  The increase in activated JNK (pJNK) observed in the repeated 
dosing model did not correlate to cell death.  Instead, this increase in pJNK 
suggests G2/M cell cycle arrest may be occurring.  This is supported by the 
increased expression of Cdk2na, a gene responsible for p16 (66).  However, we 
do not know if cellular senescence is occurring in epithelial cells in this model, 
although there are increased levels of TGF-β and other pro-fibrotic cytokines which 
are released by dedifferentiated epithelial cells in the senescent state (21).  To 
better determine if senescence is occurring, an assay for senescence-associated 
beta-galactosidase needs to be performed.    
In conclusion, we have found that fibrosis, not cell death, is the main 
pathological outcome of our more clinically relevant repeated, low dosing cisplatin 
model.  Previously developed renoprotective agents that have fared well in animal 
studies have focused on targeting cellular death pathways as a way to mediate 
renal injury.  These drugs include caspase inhibitors to block the initiation and 
execution of apoptosis (91).  Mice with caspase-1 deficiency are protected against 
cisplatin-induced AKI due to blocking activation of proinflammatory cytokines IL-
1β, IL-18, and IL-6, suggesting that targeting caspases in humans may be 
worthwhile (74).  Furthermore, pifithrin-a, a p53 inhibitor, also decreases apoptosis 
to preserve renal function during AKI (92).  Since cell death is relatively low in our 
model, it is likely that these therapies would not have a renoprotective effect in the 
repeated dosing model of cisplatin.  Our new model does provide several new 
target pathways for the development of renoprotective agents.  Our data suggest 
that maladaptive repair processes are taking place in our model.  Thus, potential 
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therapeutics include targeting G2/M cell cycle arrest to stop the process of cellular 
senescence and subsequent extended release of profibrotic cytokines.   
Furthermore, studies on the role of the immune system need to be 
performed.  While the role of different immune cell types have been somewhat 
defined in AKI models, very few studies have examined the role of these immune 
cells in fibrotic processes, other than the role of macrophages (15, 31, 57).  Thus, 
understanding the mechanistic role of immune cells may provide better insight into 
what types of cells to target to ameliorate fibrosis or protect from the development 
of fibrosis, and lead to the potential development of immunotherapies for cisplatin-
induced kidney injury.          
Furthermore, maladaptive repair processes are very similar to those 
involved in normal aging.  It is well documented that during aging, the kidney loses 
function naturally and kidney structure changes (93-95).  Namely, aging is 
associated with increased profibrotic markers, and age is a contributing factor to 
number of deaths from CKD (95, 96).  This suggests that aging plays an important 
role in kidney injury and subsequent pathologies.  In addition, cancer is regarded 
as a disease associated with age, as there are approximately 4,750 per 100,000 
patients who are 50 or older when diagnosed with cancer (97).  This is especially 
true for lung cancer patients as median age of diagnosis and of death is 70 and 72 
respectively (97).  Since lung cancer is the leading cause of cancer deaths in 
Kentucky, this implies that improving on our current model by adding in factors 
such as advanced age and lung cancer would provide a more comprehensive view 
of cisplatin-induced nephrotoxicity, and potential interplay between kidney injury 
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and lung cancer.  This is of utmost importance as fibrosis and inflammation are 
altered during aging and play a role not only in renal fibrosis, but also in cancer 
development and metastasis (98).   
  In fact, recent studies have suggested the existence of a pulmonary-renal 
syndrome in which inflammatory cytokines released by the lung during forms of 
acute lung injury (ALI) may lead to the onset of AKI (99).  Furthermore, the kidneys 
may play a role in production and elimination of inflammatory mediators of ALI (99).  
In animal models of kidney ischemia-reperfusion, Rabb et al. determined that there 
were changes in gene expression of genes involved in pulmonary regulation of salt 
and water handling in alveolar epithelial cells (100).  Furthermore, ischemia-
reperfusion models have also been associated with altered cytokine production in 
the lung, showing increased levels of IL-1β, IL-6, and IL-12 in the lung (101).  While 
these studies were done in the context of ALI, it is known that cancer is a largely 
inflammatory-mediated process (98).  Thus, it is feasible that inflammatory 
changes occurring in the lungs may influence AKI and subsequent kidney disease 
in humans, and that inflammatory processes associated with cisplatin-induced AKI 
may have an effect on lung cancer. 
Finally, the biggest advantage of our repeated low dosing model is that 
comprehensive, temporal studies can be performed by looking at changes that 
occur after each dose of cisplatin.  We have shown that one dose at 7 mg/kg does 
not have a long-term effect on renal outcome, but that four doses does.  However, 
we can now look at what happens at doses 2 and 3 as well to determine when 
fibrosis starts occurring, and correlate this to when changes in kidney function and 
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injury also start to change.  Furthermore, we can perform immune cell studies at 
each of these time points to determine when certain immune cell types are most 
important.   
Overall, our repeated, low dose cisplatin model of nephrotoxicity indicates 
that fibrosis may be a more physiologically relevant process to target in humans 
for the development of renoprotective or injury reversing agents.  Not only are we 
able to examine long-term outcomes of multiple doses of cisplatin, but our model 
affords us the ability to go back and examine changes occurring temporally to 
provide better mechanistic insight into when maladaptive repair processes are 
taking place.  Now that this model has been established, it is important to better 
characterize the processes that occur during the injury phase.  This is of 
importance as most nephrotoxic therapeutic agents have focused on amelioration 
of injury, rather than protection against injury.  By better understanding when and 











Cisplatin is a chemotherapeutic used for the treatment of many cancers but 
has nephrotoxic side effects leading to acute kidney injury (AKI).  Thirty percent of 
patients administered cisplatin will develop kidney injury, requiring the oncologist 
to withhold or reduce the next dose, leading to a less effective therapeutic regimen.  
Although recovery can occur after one episode of cisplatin-induced AKI, 
longitudinal studies have indicated multiple episodes may lead to the development 
of chronic kidney disease (CKD).  Furthermore, the severity of AKI sustained is 
also a predictor of CKD.  CKD is an irreversible disease with no current treatments 
that can progress to end-stage renal disease (ESRD), and eventual mortality. 
  Most of what is known about the complex pathophysiology of AKI has been 
studied in animal models.  The standard mouse model of cisplatin-induced AKI 
consists of one, high dose of cisplatin (> 20 mg/kg) that is lethal to the animal three 
days later.  This model doesn’t accurately reflect the dosing regimen patients 
receive (multiple doses over weeks or months), and doesn’t allow for long-term 
studies to examine outcomes associated with CKD, particularly the development 
of fibrosis.  We have developed a repeated dosing model with administration of 
cisplatin once a week for four weeks in mice. Comparison of this repeated dosing 
model to the standard dosing model demonstrated that inflammatory cytokines and 
chemokines were induced in the repeated dosing model, but levels of cell death 
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were lower in the repeated dosing model.  The repeated dosing model had 
increased levels of fibrotic markers (fibronectin, TGFβ, and α-SMA), and pathology 
revealed that interstitial fibrosis was occurring.  As fibrosis is the hallmark of CKD, 
these data demonstrate that the repeated dosing model can be used to study AKI 
to CKD progression. 
With this newly established model, we hope to identify potential targets of 
the fibrotic pathway for the development of renoprotective agents.  In order to do 
so, we need to better understand the mechanism by which AKI can progress to 
CKD.  Planned future studies include examining immune cell populations at 
various time points to determine the temporal role of immune cells during this 
transitional process.  Furthermore, we can also use this model to measure 
temporal changes in both kidney injury and function to better determine key points 
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LIST OF ABBREVIATIONS 
 
AKI: acute kidney injury   
CKD: chronic kidney disease 
RIFLE: risk injury failure loss end-stage kidney disease 
GFR: glomerular filtration rate 
SCr: serum creatinine 
Ctr1: copper transporter 1 
OCT2: organic cation transporter 2 
BCL2: B cell CLL/ lymphoma 2 
BAX: BCL2-associated X protein 
PUMA-α: p53 upregulated modulator of apoptosis 
ATN: acute tubular necrosis 
Cdks: cyclin dependent kinases 
CIP/KIP: Cdk interacting protein/ kinase inhibitory protein 
INK4: inhibitor of cyclin-dependent kinase 4 
PCNA: proliferating cell nuclear antigen 
BrdU: bromodeoxyuridine 
ER (Stress): endoplasmic reticulum (stress) 
MMPs: matrix metalloproteinases 




IR: ischemia reperfusion 
LLC-PK1: Lilly laboratories porcine kidney 1 cells 
IL-10: interleukin-10 
TNFα: tumor necrosis factor alpha 
FasL: Fas ligand 
Tim-1: T-cell immunoglobulin and mucin domain-1 
(p)SMAD3: (phospho) mothers against decapentaplegic 3 
TGFβ-(1): transforming growth factor beta- (1) 
Col1a1: collagen type 1a1 
CHOP: CCAAT/enhancer-binding protein homologous protein  
(p)JNK: c-JUN N-terminal kinase 
BUN: blood urea nitrogen 
IL6: interleukin 6 
IL1-β: interleukin 1-beta 
CXCL1: chemokine (C-X-C motif) ligand 1 
MCP1: monocyte chemotactic protein 1 
PAI-1: plasminogen activator inhibitor- 
α-SMA: alpha-smooth muscle actin 
BMP-7: bone morphogenetic protein-7 
Cdkn2a: cyclin-dependent kinase inhibitor 2a 
CTGF: connective tissue growth factor 
B2M: beta-2 microglobulin 
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SR/FG: sirius red/ fast green 
KIM-1: kidney injury molecule-1 (see also Tim-1) 
NGAL: neutrophil-gelatinase associated protein 
CC3: cleaved caspase 3 
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